GlaxoSmithKline has been given encouraging support for a stem cell gene therapy that uses an individual patient's own cells to treat a very rare immunodeficiency disorder in children. The Committee for Medicinal Products for Human Use of the European Medicines Agency , in conjunction with the Committee for Advanced Therapies , has issued a positive opinion recommending marketing authorisation for Strimvelis, GSK's brand name for the medicine to treat the ADA-SCID disorder.